Flash Finance

Jagsonpal Pharmaceuticals LimitedJAGSNPHARMCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹218.37
MCap ₹1,440 Cr · P/E 31.8
Jagsonpal Pharmaceuticals Limited — Stock analysis & AI research Jagsonpal Pharmaceuticals Limited — Multibagger AI analysis Jagsonpal Pharmaceuticals Limited — Seasonality — best & worst months Jagsonpal Pharmaceuticals Limited — Technical indicators & charts Jagsonpal Pharmaceuticals Limited — Technical setup — score, trend, support & resistance Jagsonpal Pharmaceuticals Limited — Live exchange announcements
📋 High ROCE Stocks📋 High Interest Coverage Stocks📋 Low Debt Stocks📋 Promoters Increasing Stake📋 High Promoter Holding Stocks📋 Quality Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹82 Cr
Sales · Jun 2026
+8.5% YoY
₹17 Cr
Operating Profit · Jun 2026
+19.7% YoY
20.7%
OPM % · Jun 2026
+10.1% YoY
₹13 Cr
Net Profit · Jun 2026
+20.4% YoY
₹2.00
EPS · Jun 2026
+23.5% YoY

📝 Jagsonpal Pharmaceuticals Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Jagsonpal Pharmaceuticals Limited reported revenue of ₹82 crore for the quarter ended June 2026 (Q1 FY27), up 8.5% from ₹76 crore in the same quarter last year, and up 27.7% sequentially over the March 2026 quarter.

Net profit rose 20.4% year-on-year to ₹13 crore, from ₹11 crore. Earnings per share (EPS) came in at ₹2.00.

Operating profit stood at ₹17 crore — an operating margin (OPM) of 20.7%, compared with 18.8% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Jagsonpal Pharmaceuticals Limited posted revenue of ₹287 crore, a growth of 6.9% over FY25, with a net profit of ₹43 crore (down 22.2% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹294 crore with a net profit of ₹45 crore.

Valuation snapshot

At the current price of ₹218.37, JAGSNPHARM has a market capitalisation of ₹1,440 crore and a trailing P/E of about 31.8.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 24th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 69.36%, foreign institutional investors (FIIs) 2.46%, domestic institutional investors (DIIs) 0.31%, public shareholders 27.88% of Jagsonpal Pharmaceuticals Limited.

Promoter holding rose from 67.89% to 69.36% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹1,440 Cr
Current Price ?
₹218.4
P/E ?
31.81below ind
Industry P/E ?
37.20
P/B ?
5.22
P/S ?
4.91
P/FCF ?
30.64
Enterprise Value ?
₹1,448 Cr
EV/EBITDA ?
23.79
PEG ?
1.99
Earnings Yield ?
3.6%
Dividend Yield ?
1.14%
Profitability & Returns
Sales (TTM) ?
₹294 Cr
OPM ?
20.7%
Profit after tax (TTM) ?
₹45 Cr
EPS (TTM) ?
₹6.87
ROCE ?
23.0%
ROE ?
16.4%
ROA ?
14.3%
Growth
Sales — latest qtr ?
₹82 Cr
PAT — latest qtr ?
₹13 Cr
YoY qtr sales growth ?
8.5%
YoY qtr profit growth ?
20.4%
Sales growth (3y) ?
7%
Sales growth (5y) ?
9%
Profit growth (3y) ?
16%
Profit growth (5y) ?
21%
Financial Health
Debt ?
₹8 Cr
Debt to Equity ?
0.03
Interest Coverage ?
47.2
Current Ratio ?
N/A
Ownership
Promoter holding ?
69.36%
Change in promoter holding ?
1.82%
Pledged percentage ?
N/A
Market
Return 3 months ?
-2.5%
Return 6 months ?
13.8%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 5560584758617574597674736482 +8.5% +27.7%
Operating Profit 5983710161691416161117 +19.7% +52.3%
Other Income 32239-2226333133 +6.0% -5.4%
Interest 00000000000000 -100.0% -100.0%
Depreciation 00001122222222 -14.9% -13.8%
Profit Before Tax 710105147153991417151218 +24.7% +53.1%
Net Profit 677411511327111311913 +20.4% +48.4%
EPS 0.851.141.140.604.190.811.734.820.991.621.891.641.312.00 +23.5% +52.7%
OPM % 9.8% 14.3% 14.5% 7.2% 11.8% 16.7% 21.8% 21.4% 14.9% 18.8% 22.1% 22.3% 17.4% 20.7% +10.1% +19.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹269 Cr ₹287 Cr ₹294 Cr +6.9%
Operating Profit ₹51 Cr ₹58 Cr ₹61 Cr +13.7%
OPM % 19.01% 20.22% 20.73% +6.4%
NPM % 20.60% 15.00% 15.42% -27.2%
Other Income ₹28 Cr ₹10 Cr ₹10 Cr -64.4%
Depreciation ₹8 Cr ₹9 Cr ₹9 Cr +16.2%
Interest ₹1 Cr ₹1 Cr ₹1 Cr +6.2%
EBIT ₹43 Cr ₹49 Cr ₹52 Cr +13.2%
PBT ₹70 Cr ₹58 Cr ₹61 Cr -17.7%
Tax — — — —
Net Profit ₹55 Cr ₹43 Cr ₹45 Cr -22.2%
EPS ₹8.35 ₹6.46 ₹6.84 -22.6%
Material Cost — — — —
Employee Cost — — — —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 13131313 +0.0%
Reserves 146174227263 +15.9%
Borrowings 6998 -11.1%
Other Liabilities 30212932 +10.3%
Total Liabilities 195217278317 +14.0%
Fixed Assets 2499485 -9.6%
CWIP 0000 —
Investments 1000 —
Other Assets 170208184231 +25.5%
Total Assets 195217278317 +14.0%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 47355547 -14.5%
Cash from Investing Activity -58-25-45-36 +20.0%
Cash from Financing Activity -0-9-12-12 +0.0%
Net Cash Flow -112-2-1 +50.0%
Free Cash Flow 48359147 -48.4%
CFO/OP 158%189%124%101% -18.5%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 32191822 +22.2%
Inventory Days 82685851 -12.1%
Days Payable 66353740 +8.1%
Cash Conversion Cycle 48533933 -15.4%
Working Capital Days 3452911 +22.2%
ROCE % 25%17%23%23% +0.0%

👥 Shareholding (latest 4 periods)

Metric Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 67.54%67.39%67.89%69.36% +2.2%
FIIs 2.12%2.12%2.44%2.46% +0.8%
DIIs 0.08%0.15%0.22%0.31% +40.9%
Public 30.25%30.34%29.44%27.88% -5.3%
No. of Shareholders 24,65324,89526,26424,826 -5.5%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Jagsonpal Pharmaceuticals Limited's revenue in Q1 FY27?
Jagsonpal Pharmaceuticals Limited reported revenue of ₹82 crore for the quarter ended June 2026 (Q1 FY27), up 8.5% from ₹76 crore in the same quarter last year, and up 27.7% sequentially over the March 2026 quarter.
What was Jagsonpal Pharmaceuticals Limited's net profit in Q1 FY27?
Net profit rose 20.4% year-on-year to ₹13 crore, from ₹11 crore. Earnings per share (EPS) came in at ₹2.00.
What is JAGSNPHARM's market capitalisation and P/E ratio?
At the current price of ₹218.37, JAGSNPHARM has a market capitalisation of ₹1,440 crore and a trailing P/E of about 31.8.
Who owns Jagsonpal Pharmaceuticals Limited? (shareholding pattern)
As of Jun 2026, promoters held 69.36%, foreign institutional investors (FIIs) 2.46%, domestic institutional investors (DIIs) 0.31%, public shareholders 27.88% of Jagsonpal Pharmaceuticals Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI